Floatz logo

Semaglutide

Obesity Disorder

Floatz Rating
BBB72/100
Confidence
Indicative
v0.2
Sponsor
Ali Aminian
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
77High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
Metabolic Surgery for Atrial Fibrillation Elimination
Not Yet Recruiting
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Not Yet Recruiting
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Not Yet Recruiting
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
Not Yet Recruiting
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
Not Yet Recruiting
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Not Yet Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Recruiting
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Not Yet Recruiting
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Not Yet Recruiting
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Not Yet Recruiting
Show 111 more trials
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
Recruiting
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
Not Yet Recruiting
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Recruiting
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Recruiting
A Study of CS060380 Tablets in Patients With MASH and Obesity
Recruiting
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant
Not Yet Recruiting
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Recruiting
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
Not Yet Recruiting
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Recruiting
The Evira Study: Additional Support During Obesity Treatment
Recruiting
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
Active Not Recruiting
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Active Not Recruiting
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Recruiting
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Withdrawn
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Recruiting
Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity
Not Yet Recruiting
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Active Not Recruiting
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
Not Yet Recruiting
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Recruiting
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Active Not Recruiting
Semaglutide Treatment in Type 1 Diabetes
Not Yet Recruiting
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Recruiting
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Recruiting
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
Recruiting
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
Active Not Recruiting
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Recruiting
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
Recruiting
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Recruiting
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Active Not Recruiting
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Recruiting
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Enrolling By Invitation
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
Completed
Tailoring Obesity Treatment Trial
Withdrawn
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Active Not Recruiting
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Not Yet Recruiting
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
Recruiting
Semaglutide's Weight Loss Effects in Obesity
Not Yet Recruiting
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Active Not Recruiting
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Recruiting
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
Active Not Recruiting
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
Completed
Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients
Active Not Recruiting
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
Completed
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Completed
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Not Yet Recruiting
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
Recruiting
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
Recruiting
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Completed
Semaglutide in Treatment of Obesity
Completed
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Active Not Recruiting
DUTCH Weight Control in Atrial Fibrillation Study
Recruiting
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
Completed
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Recruiting
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Completed
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Completed
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Recruiting
Semaglutide 2.4mg for Low Responders After Bariatric Surgery
Not Yet Recruiting
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Completed
Semaglutide for Post-Smoking Cessation Weight Management
Recruiting
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Completed
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Active Not Recruiting
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Completed
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Completed
Semaglutide and Physical Activity for Obesity and Multimorbidity
Active Not Recruiting
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Completed
Feasibility of Semaglutide in Advanced Lung Disease
Recruiting
Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
Recruiting
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Completed
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Recruiting
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Completed
Anti-obesity Pharmacotherapy and Inflammation
Active Not Recruiting
Semaglutide and Vascular Regeneration
Unknown
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Completed
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
Completed
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Completed
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Completed
Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
Active Not Recruiting
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Recruiting
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Completed
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Terminated
Latino Semaglutide Study
Completed
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
Completed
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active Not Recruiting
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
Withdrawn
Genetics of the Acute Response to Oral Semaglutide
Recruiting
Semaglutide Use in Elderly Obese Patients
Completed
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
Completed
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects
Completed
Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV
Recruiting
Pharmacogenetics of Response to GLP1R Agonists
Recruiting
Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)
Active Not Recruiting
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
Completed
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
Completed
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Completed
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Completed
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Terminated
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Completed
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Completed
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Completed
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
Completed
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Active Not Recruiting
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Completed
Once Weekly GLP-1 in Persons With Spinal Cord Injury
Completed
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
Completed
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
Completed
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
Completed
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Completed
A Toolbox Approach to Obesity Treatment in Primary Care
Completed
PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults
Not Yet Recruiting

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Obesity Disorder

AssetSponsorPhaseRating
Semaglutide (this asset)Ali AminianApprovedBBB · 72
vi-0521VIVUS LLCP4BBB
TirzepatideRoyal North Shore HospitalP4BBB
asc30Ascletis Pharma (China) Co., LimitedP2BBB
PhentermineRussell McCulloh, MDP4BBB
SurvodutideBoehringer IngelheimP3BBB
Deoxycholic AcidUniversity of California, San DiegoP4BBB
Efsubaglutide AlfaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolP4BBB
CagrilintideNovo Nordisk A/SP3BBB

+42 more in the Obesity Disorder cohort

Other indications for Semaglutide

IndicationSponsorPhaseRating
Metabolic DiseaseP4A · 81
Polycystic Ovary SyndromeP4BBB · 79
Type 2 Diabetes MellitusP4BBB · 78

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Semaglutide in Obesity Disorder. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/semaglutide-obesity-disorder

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →